CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer

Background: Androgen deprivation therapy (ADT) is still the first-line treatment of prostate cancer (PCa). However, after a certain period of therapy, primary PCa inevitably progresses into castration-resistant PCa (CRPC). Enzalutamide (Enz) is an androgen receptor (AR) signal inhibitor which can de...

Full description

Bibliographic Details
Main Authors:	Chen, X. (Author), Jian, J. (Author), Wang, L. (Author), Wang, X. (Author), Wu, D. (Author), Wu, G. (Author), Wu, Y. (Author), Xu, C. (Author)
Format:	Article
Language:	English
Published:	BioMed Central Ltd 2022
Subjects:	Castration-resistant prostate cancer Cyclin-dependent kinase 6 Differentially expressed genes Enzalutamide Hub gene Therapeutic target
Online Access:	View Fulltext in Publisher

Similar Items

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: Luo J, et al.
Published: (2016-11-01)

A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research
by: Laccetti AL, et al.
Published: (2020-12-01)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
by: Taro Iguchi, et al.
Published: (2019-04-01)

Safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: a phase II, multicenter, single-arm, open-label study
by: B. Ya. Alekseev, et al.
Published: (2018-04-01)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
by: Shinichi Sakamoto, et al.
Published: (2019-04-01)

Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study
by: Huanyi Lin, et al.
Published: (2021-04-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy
by: Wenjun Jiang, et al.
Published: (2020-03-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
by: Wei Zhang, et al.
Published: (2017-01-01)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
by: Yi-Ting Lin, et al.
Published: (2021-05-01)

Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
by: Luigi Rossi, et al.
Published: (2021-03-01)

Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
by: Zhongbo Du, et al.
Published: (2021-03-01)

Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data
by: P. V. Mazin, et al.
Published: (2018-01-01)

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
by: Zhe Hong, et al.
Published: (2021-07-01)

NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
by: B. Ya. Alekseev
Published: (2018-10-01)

Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
by: Qingzhong Hu, et al.
Published: (2013-07-01)

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
by: Taizo Uchimoto, et al.
Published: (2021-01-01)

High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients
by: Yu-Ting Hsieh, et al.
Published: (2021-08-01)

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
by: Sumanta K. Pal, et al.
Published: (2019-04-01)

Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer
by: Shiv Verma, et al.
Published: (2020-11-01)

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial
by: Nancy Devlin, et al.
Published: (2017-06-01)

Pharmacoeconomic analysis of enzalutamide and abiraterone for treatment of chemotherapy naive patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2017-10-01)

New developments in the treatment of castration resistant prostate cancer
by: Roxanne Wadia, et al.
Published: (2014-08-01)

Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2020-07-01)

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases
by: S. V. Popov
Published: (2020-12-01)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
by: Hung-Ming Lam, et al.
Published: (2018-05-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-07-01)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
by: Alexandra Vander Ark, et al.
Published: (2018-05-01)

SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES
by: A. S. Markova, et al.
Published: (2018-10-01)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
by: Kouji Izumi, et al.
Published: (2017-10-01)

Second-line hormonal therapy with the enzalutamid in patients with castrate-resistant prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2016-09-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
by: Neil M. Schultz, et al.
Published: (2018-09-01)

Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01)

Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide
by: B. Ya. Alekseyev, et al.
Published: (2019-12-01)

The National Registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian Federation
by: O. B. Karyakin, et al.
Published: (2019-10-01)

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience
by: Rachel Raju, et al.
Published: (2021-06-01)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
by: Tucci M, et al.
Published: (2018-10-01)